Focus: Dragonfly Therapeutics is a public biotechnology company focused on immuno-oncology drug development, headquartered in Waltham, MA and founded in 2016. The company operates in the oncology therapeutic area with a pipeline of early-stage candidates.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Suitable for early-career or mission-driven scientists willing to accept execution risk in exchange for potential ownership upside in a focused oncology biotech.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Dragonfly Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dragonfly Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo